Last reviewed · How we verify
SB705498
At a glance
| Generic name | SB705498 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intranasal SB-705498 in Allergic Rhinitis (AR) Patients (PHASE2)
- SB-705498 Dental Pain Study After Tooth Extraction (PHASE2)
- Sb-705498 Rectal Pain Study (PHASE2)
- SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis (PHASE2)
- A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model (PHASE1)
- Intranasal SB-705498 in Healthy Volunteers (PHASE1)
- Investigation of Topical SB705498 on Healthy Volunteers (PHASE1)
- Intranasal SB-705498 in Non-allergic Rhinitis Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB705498 CI brief — competitive landscape report
- SB705498 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI